

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

PRO PHARMACEUTICALS INC
Form 8-K
January 16, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

January 16, 2007
Date of Report (Date of earliest event reported)

PRO-PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

NEVADA
(State or Other Jurisdiction
of Incorporation)

000-32877
(Commission File Number)

04-3562325
(IRS Employer
Identification No.)

7 WELLS AVENUE
NEWTON, MASSACHUSETTS
02459
(Address of Principal Executive Offices) (Zip Code)

(617) 559-0033
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

=====

Item 5.02. Departure of Directors or Principal Officers; Election of Directors;

Edgar Filing: PRO PHARMACEUTICALS INC - Form 8-K

Appointment of Principal Officers.

On January 16, 2007, we received a letter from Burton C. Firtel, one of our directors, notifying us of Mr. Firtel's resignation from the Board of Directors of Pro-Pharmaceuticals, Inc. effective immediately. A copy of Mr. Firtel's resignation letter is filed herewith as Exhibit 17.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

17.1 Letter of Burton C. Firtel to David Platt, Chief Executive Officer of Pro-Pharmaceuticals, Inc., dated January 11, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

Date: January 16, 2007

By: /s/ David Platt

David Platt
Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Exhibit
17.1	Letter of Burton C. Firtel to David Platt, Chief Executive Officer of Pro-Pharmaceuticals, Inc., dated January 11, 2007